The Economic Times
English Edition
| E-Paper
Search
+

    Shares of Aurobindo Pharma fall as Nifty drops

    Synopsis

    On the technical charts, the 200-day moving average of the stock stood at Rs 866.57.

    Reuters
    On an immediate basis, 15,770/52,500 and 15,850/52,700 levels would be major hurdles.
    Shares of Ltd. slipped 1.01 per cent to Rs 688.7 in Tuesday's trade as of 01:51PM (IST). It hit a high of Rs 699.9 and low of Rs 687.0 during the session.

    The stock quoted a 52-week high price of Rs 1063.75 and a low of Rs 660.1. The return on equity for the stock stood at 24.32 per cent. About 48,093 shares have changed hands on the counter so far.

    The stock's beta value, which measures its volatility in relation to the broader market, stood at 1.06.

    The scrip has been an underperformer, down 19.22 per cent in the past one year in comparison with a 39.57 per cent gain in Sensex.

    Technicals
    On the technical charts, the 200-day moving average (DMA) of the stock stood at Rs 660.1 on November 16, while the 50-DMA was at Rs 716.38. If a stock trades well above 50-DMA and 200-DMA, it usually means the immediate trend is upward. On the other hand, if the stock trades well below 50-DMA and 200-DMA both, it is considered a bearish trend and if trades between these averages, then it suggests the stock can go either way.

    Promoter/FII Holding
    Promoters held 48.76 per cent stake in Aurobindo Pharma Ltd. as of 30-Sep-2021. Mutual funds and foreign institutional investors held 9.28 per cent and 21.71 per cent stake.

    Pick the best companies to invest

    BECOME AN ETPRIME MEMBER
    (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Read before you invest. Insights on Aurobindo Pharma Ltd.. Explore Now
    The Economic Times

    Stories you might be interested in